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Lewis recipients of orthotopic ACI livers had perma-
nent graft acceptance induced with 3 doses of i.m. 
FK506 in the early postoperative period. They were 
studied 100 and 300 days posttransplantation. The re-
cipients rejected ACI as well as Brown Norway (BN) 
(third-party) skin grafts. and had lymphocytes with sub-
stantial reactivity by mixed lymphocyte culture testing 
against ACI and third-party (BN) alloantigens. Lympho-
cyte subset redistribution had not occurred in the pe-
ripheral blood or spleens of these animals. and there was 
no evidence of suppressor cell activation by in vitro and 
in vivo tests. Graft-versus-host reactivity in splenic 
lymphoid tissues of these recipients was demonstrated 
with the popliteal lymph node assay. Attempts at adap-
tive transfer with recipient lymphocytes were unsuc-
cessful. Heart graft acceptance was far more difficult to 
accomplish than liver graft acceptance, and probably 
was never permanent. ACI heart graft prolongation in 
LEW recipients after a brief induction with FK506 
lasted for no more than 3 months in most animals. The 
temporary heart graft acceptance was specific for hearts 
of the original ACI donor strain but not for ACI skin. 
Results of studies of lymphocyte subsets and suppressor 
cell activity were similar to those in the liver recipients. 
These studies illustrate how poorly graft acceptance is 
understood and how badly further work is needed to 
clarify its mechanism. 
In a companion study (l), we demonstrated in rats that a 3-
day course of FK506 beginning on postoperative day 4 or even 
later allows the long or permanent survival of heterotopic heart 
(2, 3) or orthotopic liver homografta. Similar but less-repro-
ducible observations have been made after kidney transplan-
tation in dogs and baboons (4,5) and liver transplantation in 
dogs (4). In the past, the induction of long graft survival in 
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these latter species has been seen with a brief course of treat-
ment with other agents such as antilymphocyte serum (6) but 
this has been uncommon. 
The potential immunological mechanisms that have been 
proposed to explain the prolonged graft acceptance after dis-
continuance of longer courses of therapy include modulation of 
graft antigen expression (7-9), depletion of cIonally active cells 
following immune suppression and exposure to the graft (10-
12), antigen/antibody blockade of effector cells (13, 14), and 
the activation of suppressor cells (15-18). Cyclosporine-in-
duced survival of heart allografts has been shown to be the 
result of early nonspecific immunosuppression, followed by the 
eventual emergence of active suppression that is specific for 
the donor organ (19). 
In the experiments reported here, we have examined the 
immunological characteristics in rats that had prolonged heart 
and liver graft survival following a short course of FK506 
administration. 
MATERIALS AND METHODS 
Animals. Long'surviving graft recipients: Inbred male rats of Lewis 
(LEW) (RTl'), ACI (RTl·). and Brown Norway (BN) (RTl") strains. 
and their F\ hybrid (LEWXACI) F, were purchased from Harlan 
Sprague Dawley Inc. (Indianapolis, IN) and Simonsen Laboratory 
(Gilroy, CAl. Most of the animals studied had long-functioning heart 
or liver allografts following a short~ourse treatment of intramuacular 
FK506. as described in a companion study (1). The LEW recipients of 
ACI heart grafts were given 3 i.m. doses of 1.28 mg/kg FK506 on days 
4, 5, and 6 posttransplantation. With this treatment regimen. the 
median survival of ACI heart grafts was prolonged from a control of 6 
to 91.0 days (J). The animals were studied on days 14, 28, and more 
than 70 days after allografting. 
The LEW recipients of ACI liver allografts received 3 or 4 i.m. doses 
of 1.28 mg/kg FK506 on days 0-2. 2-4, ~K or 4-6. The majority oCthe 
rsts treated at any of these times survived indefinitely. and these long-
term survivors were studied at 100 or 300 days after grafting. 
Fresh transplants: In some of the special experimental grouPS. freah 
ACI·to-LEW heart or liver transplants were performed with the same 
surgical techniques used when the chronically surviving animals were 
originally transplanted. Full·thickness skin transplantation was also 
performed in a special group (see below). 
Tests after carditJc transplantation. Placement of second cardiac 
allografts: Recipients of ACI hearts were given a second heart from an 
-
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ACI (original donor strain) or BN (third-party) donor, either 2 or 4 
weeks after the primary transplantation. The Be(;ond heart grafts were 
transplanted into the subeutis of the ventral neck of recipienta using 
the modified method described by Heron (20). To control for the 
possibility of a residual FK506 effect from treatment of the primary 
graft, a control group of LEW rats were given the same 3 doses of 
FK506 without ACI heart grafting and then grafted with ACI or BN 
hearts by Heron's cervical technique 2 or 4 weeks later. 
Skin grafts in heart recipients: Skin grafta from either ACI or BN 
strains were placed on LEW recipients 28 days after cardiac allografts 
from either ACI or BN donon. Full-thickness 1-cm2 tail skin grafts 
were sutured to the flanks of the recipients, and a plaster cast was 
applied for one week. Tbe grafts were inspected daily after removal of 
the casts. Rejection was considered to have occurred when the graft 
exhibited complete epithelial necrosis as judged grossly. 
Influence of splenectomy on heart graft survival: The immunosup-
pressive effect of CsA was reported to be reduc~ in rats with splenec-
tomy (21), possibly because of the loss of 8plenic suppressor cells. 
Consequently, LEW recipients had splenectomy immediately before 
they were given an ACI heart and then treated with 1.28 mg/kg of Lm. 
FK506 on days 4, 5, and 6 posttransplantation. 
Lymphocyte subset analysis: Spleen cells were prepared by mincing 
tissue into RPMI·1640 (Gibeo, Grand Island, NY) and then washing 
twice in the culture medium. Peripheral blood lymphocytes were iso-
lated from heparinized blood by Ficoll-Hypaque density gradient cen-
trifugation (s.g. 1.090) and washed twice in RPMI-1640. Graft-infil-
trating cells were obtained from the heart grafts by mincing 1-mm3 
pieces in RPMI-1640, and then slibjecting the suspension to vigorous 
mechanical agitation and filtration through a fine nylon mesh (Tetko 
Inc., Briarcliff Manor, NY). 
Surface-associated marken on the lymphocytes were identified using 
primary antirat monoclonal antibodies with defined specificity (Accu-
rate Scientific, Westbury, NY): W3/25 (CD4; helper/inducer T cella, 
macropbages), OX8 (CD8; cytotoxic/suppressor T cella, natural killer 
cells), OX19 (CD5; pan T cell), and OX6 (MHC class Ill. Test cells 
(lxloe) suspended in 1.0 ml of staining buffl'r (PBS. pH 7.4, 0.1% 
sodium azide, 2% FCS) were incubated with primary monoclonal an-
tibodies (1:100 final dilution) for 30 min at 4 ·C, washed twice. and then 
resuspended with a secondary antibody consisting of a FITC.labeled 
rat antimouse IgG, heavy- and light-chain-specific (Boehringer-Mann-
heim, Indianapolis, IN). After a 30-min incubation at 4'C, the cells 
were washed twice and analyzed for fluores('l'nt staining using the 
FACSTAR IV flow cytometer (Becton-Dickinson, Lincoln Park, NJ). 
Tests after liver transplantation. Skin grafts in liver recipients: The 
skin grafts from ACI or BN donors were plalD~ on LEW recipients of 
ACI liven, 100 or 300 days after transplantAtion. The experimental 
endpoint was duration of skin graft survival. 
Graft-versus-host reactivity: Spleen ~lfs from the Mtolerant" liver 
recipients were tested for the presl'nce of antidonor (ACI) alloreactive 
T cells, using the popliteal lymph node assay E:?~lK Spleen cells (2x10') 
from LEW recipients of ACI liver grafts, from normal LEW rats, or 
from normal FI rats (ACIxLEW), were suspl'ndt'd in 0.1 ml of medium. 
and injected subcutsneously into the footpads of young sex-matched 
(ACIxLEW) FI recipients. The popliteal nodf.s were removed and 
weighed 7 days later. If the injected cells did not contain alloreactive 
T cells, no modification of the popliteal nodl's 'A-ould be expected. 
Mixed lymphocyte reaction and suppressor r.lls: One-way MLR was 
performed using mesenteric lymph node cells from LEW liver recipients 
to which irradiated (2000 rads) spleen cells from donor strain (ACI) or 
third·party strain (EN) were added. Spleen r.Us and lymph node cells 
were prepared by mincing excised tiasul! into RPMI-1640 culture me-
dium. They were isolated by centrifugation over a Ficoll-Hypaque 
gradient. Triplicate cultures of 1xIO' respondf.r cells and 2x 10' stim-
ulator cells were established in 8 final voluml' of 0.2 ml of RPMI-1640 
culture medium supplemented with 25 mM HEPES buffer, 5XlO-6 M 
2·mercaptoethanol, penicillin (100 U/ml). stl'l'ptomycin (100 Jlg/ml), 
and 10% heat· inactivated rat serum in round-bottomed microculture 
plates. Cultures were incubated in a humidifit'd atmosphere of 5% CO2 
in air for 5 days at 37·C. Then 16 hr before the termination of the 
culture, 1 )lCi of 'Ii-thymidine was added to each well. Cultures were 
harvested with 8 multiple sample h8r\'eSter (Skatron Inc., Sterling, 
VA) and 'H-thymidine uptake was determined by liquid scintillation 
spectrometry. 
Suppressor cell reactivity in the MLR was also assayed by mixing 
lymph node cells obtained from normal (LEW) rats with the lymph 
node cells from LEW rats that were bearing long-surviving liver grafts; 
cell ratios were 1:1, 1:3, and 1:10. A total of 2XIO· of the mixture of 
responding cells were stimulated in vitro with 2X10' irradiated ACI or 
BN spleen cells. 
Lymphocyte subset analysis: The fluorescence staining method was 
the same as in the heart experiments. 
Adoptive transfer assay after heart and liver transplantation. The 
presence of cells with suppressor activity in animals with chronically 
tolerated heart and liver grafts was determined using an in vivo 
adoptive transfer assay of spleen cells.. Spleens were removed from 
animals that had heart graft survival for 28 days or >70 days and from 
liver recipients that had graft survival of 100 or 300 days. Single-cell 
suspensions were prepared by mincing the recipient spleens into RPM!-
1640. A total of 200XIO· splenic lymphocytes from these LEW heart 
or liver recipients was injected intravenously into sublethally irradiated 
(250 rads) or nonirradiated syngeneic LEW recipients immediately 
after the placement of 8 fresh ACI cardiac or liver graft. Survival of 
the graft was the endpoint of this experiment. 
StIltisticaJ. analysis. Results were analyzed for statistical significance 
by the unpaired two-tailed Student's t test, and differences considered 
statistically significant if P<O.Ol. Because graft survival results were 
variable, significance was determined in all survival experiments with 
the Wilcoxon rank sum test. There was a difference using the 2 
techniques only in groups 4 and 5 in Table 4. 
RESULTS 
Results after cardiac transplantation. Strain specificity of 
graft acceptance: The test results and controls are summarized 
in Table 1. In essence, the transplantation of a primary ACI 
heart to a Lewis recipient with delayed 3-dose FK506 therapy 
allowed prolonged survival of a 5eC{)nd ACI heart transplanted 
either 2 (group 8) or 4 weeks (group 10) after the transplanta-
tion of the first heart. Part of this prolongation in the 2-week 
but not the 4-week experiments may have been due to residual 
immunosuppression from the original FK506 therapy, which 
was demonstrable in control groups 4 and 5 but not groups 6 
and 7. Eventually, the second hearts were rejected, usually 
about when the primary grafts were rejected. 
In contrast, BN hearts transplanted 2 (group 9) and 4 weeks 
(group 11) after primary ACI grafts had no prolongation what-
ever, compared with the controls of group 2. 
Organ specificity of graft acceptance: ACI and BN skin grafts 
are normally rejected by LEW recipients in 11 and 14 days, 
respectively (control data are shown in Table 2). The presence 
of an ACI heart transplantation 4 weeks earlier with FK506 
did not effect the rejection of either ACI or BN skin grafts 
(groups 12 and 12', Table 1). 
Influence of splenectomy: The results after heart transplan-
tation were not significantly different with or without splenec-
tomy in the animals treated with FK506 (Table 3). 
Lymphocyte subset analysis 7 days after heart transplanta-
tion with FK506: FK506 treatment was done on days 4, 5, and 
6. The total number of cells infiltrating the cardiac allografts 
was markedly reduced after treatment with FK506, compared 
with the findings in untreated animals (1). In 5 grafts studied 
on day 7 in animals given 1.28 mg/kg FK506 i.m. on days 4, 5, 
and 6, the proportion ofaX19, aXB, w3/25, and aX6 lympho-
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TABLE 1. Specificity of the graft acceptance in LEW recipients after ACI cardiac transplantation with FK506 
First graft Second graft 
FK Group 
MST' po treatment' Timing Tissue Donor MST po n Donor n (weeks)· 
7 ACI 6.0 (6-7) 
2 6 EN 11.5 (11-13) 
3 6 ACI 91.0 (23-146) + 
4 + 7 2 Heart ACI 10.0 (9-19) <O.OOl· -
5 + 7 2 Heart BN 34.0 (15-42) <0.01·· -
6 + 5 4 Heart ACI 7.0 (IH!) NS· 
7 + 5 4 Heart BN 9.0 (7-20) NS·· -
8 6 ACI 63.5 (37-95) NS··· + 6 2 Heart ACI 45.0 (15-72) <0.01' <0.01 .... 
9 5 ACI 54.0 (42-79) NS·" + 5 2 Heart BN 14.0 (10-17) NS·· < 0.01···· 
10 6 ACI 59.5 (48-78) NS·" + 6 4 Heart ACI 27.5 (1842) <0.01· <0.001···· 
11 4 ACI 56.0 (53-76) NS··· + 4 4 Heart BN 10.0 (6-11) NS·· NS···· 
12 5 ACI 36.0 (35-40) NS··· + 5 4 Skin ACI 10.0 (9-10) NS····· 
12' 5 ACI 36.0 (35-40) NS··· + 5 4 Skin BN 12.0 (12-14) NS····· 
• Median survival time (range) in days. 
b P value (Wilcoxon rank sum test) • vs. group 1; .. vs. group 2; ••• vs. group 3; •••• vs. treated control groups (groups 8 VS. 4, 9 VS. 5, 10 VB. 
6, 11 VB. 7); ..... VB. untreated control groups of skin grafting (Table 3). 
e 1.28 mg/kg intramuscularly on days 4, 5, and 6 after first ACI heart allografting. 
• Challenge with secondary grafting at either 2 weeks or 4 weeks following first grafting. 
TABLE 2. Survival of donor and third-party skin grafts on FK506-
treated LEW rats with established ACI liver grafts 
Recipient Donor n Skin graft survival MST po (days) (days) 
LEW (normal) ACI 5 la, 10, 11, 11, 11 11.0 
BN 5 14, 14, 14, 14, 15 14.0 
LEW (100 days after ACI 6 10, la, 11, 11, 14, 15 11.0 NS· 
ACI liver grafting) 
BN 6 la, 14, 14, 14, 15, 16 14.0 NS·· 
LEW (300 days after ACI 3 14, 14, 14 14.0 NS· 
ACI liver grafting) 
BN 3 15, 16, 18 16.0 NS·· 
• P (Wilcoxon rank sum test): • VB. survival of ACI skin grafts in 
normal LEW rata; •• VB. survival of BN skin grafts in normal LEW 
rata. 
cytes in the diminished infUtrate was not significantly different 
from that in the cardiac grafts of untreated controls (data not 
shown). The subset proportions were similar in the spleen in 3 
other similarly treated heart recipients, although there was an 
increased expression of class II histocompatibility antigens 
(OX6) in the peripheral blood lymphocytes of these versus 
untreated animals (P<.OOOl). Three nonoperated Lewis rats 
given the same FK506 treatment had no significant changes in 
lymphocyte subset distribution in their spleens or peripheral 
blood. 
Results after liver transplantation. Organ specificity of graft 
acceptance: Both ACI and BN skin grafts were rejected in the 
normal way 100 days or 300 days after ACI-to-LEW liver 
transplantation (Table 2). 
Graft-versus-host reactivity (popliteal lymph node assay): 
After the injection of parental strain (LEW) splenic lympho-
cytes into F I footpads, draining popliteal lymph nodes (PLN) 
ofF, hybrids were noted to have significantly increased weight 
bDem PLN weight: 92.88±1.89 mg), whereas the splenic lym-
phocytes from the syngeneic F 1 hybrid did not induce PLN 
hypertrophy (5.83±1.6 mg) (Fig. 1). The splenic lymphocytes 
from FK506-treated LEW recipients with permanent accept-
ance of ACI liver grafts demonstrated an intermediate GVHD 
response between the positive and negative controls (PLN 
weight: 35.81±8.12 mg). This showed that LEW lymphocytes 
from the spleen of unaltered controls-and, to a lesser extent, 
from animals with permanent liver graft acceptance-were 
capable of recognizing the ACI alloreactivity of the Fl test 
animal. 
Mixed lymphocyte reactivity and suppressor cells: Mesen-
teric lymph node cells from 6 LEW recipients of permanently 
accepted ACI liver grafts responded to irradiated ACI and BN 
lymphocytes (Fig. 2). There were no exceptions, although the 
degree of proliferation stimulated by the ACI alloantigens was 
more variable than with BN. 
In the same MLR system, suppressor cell activity was looked 
for in lymph node cells from the LEW rats bearing ACI livers. 
Lymph node cells from the grafted rats failed to suppress the 
MLR when lymphocytes from unmodified LEW donors were 
exposed to irradiated ACI or BN lymphocytes (Fig. 2), indic&t-
ing that the liver graft acceptance was not associated with 
suppressor cell activity. 
Lymphocyte subset distribution: In 3 LEW recipients 100 
days after liver grafting, lymphocytes from the spleen and 
peripheral blood did not have a changed proportion of OX19, 
OX8, w3/25, and OX6 lymphocytes compared with normal 
nonoperated controls (data not shown). 
Adoptive transfer after Mart and liver transpinntation. Sup-
pressor cell activity in spleens in FK506-treated recipients of 
either cardiac or liver allografts was looked for in adoptive 
transfer experiments. 
Splenic lymphocytes from cardiac recipients: Control LEW 
rats subjected to 250 rads total-body irradiation alone or irra-
diation plus transfer of 200x 10- splenic lymphocytes from 
normal LEW rats rejected ACI heart grafts with an MST of 
7.0 days (group 2) and 6.5 days (group 3), respectively (Table 
4). Transfer of 200xI08 lymphocytes from recipients with sur-
viving heart grafts for 28 days or more than 70 days did not 
consistently prolong graft survival (groups 4 and 5), although 
there were more examples of long graft survival than in the 
controls. The mean prolongation was not significant with the 
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TABLE 3. Influence of splenectomy on heart graft survival in FK506·trested animals 
Group Treatment 
1b 
2b 1.28 mg/kg, days 4, 5, 6 
3 Splenectomy 
4 1.28 mg/kg, days 4, 5, 6 with 
splenectomy' 
• P value (Wilcolon rank sum teat) group 2 vs. 4: NS. 
b Control values from Table 1. 
, Splenectomy was performed on the day of grafting. 
• Animal was sacrificed with pulsating graft. 
n 
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FIGURE 1. Graft·versus·bost reactivity of spleen cells from LEW 
rats with permanently accepted ACI liver grafts, as demonstrated with 
the popliteal lymph node assay in FI hybrid (AClxLEW) test animals. 
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FIGURE 2. Miled lymphocyte reaction of lymph node cells taken 
from LEW rata bearing permanently accepted ACI liver grafta. Note 
the substantial antidonor (anti·ACI) reactivity. 
Student's t tests (group 4., P=.02; group 5, P=.07) but was with 
the Wilcoxon rank sum test (P<O.Ol). 
Splenic lymphocytes from liver recipients: Splenic lympho-
cytes 100 and 300 days after liver grafting did not alter the 
survival of ACI liver grafts transplanted into naive LEW recip-
ients (Table 5). 
Graft survival MST p-(days) (days) 
6,6,6,6,6,7,7 6.0 
23, 51, 89, 93, 98, 146 91.0 <0.01 
6,6,6 6.0 NS 
30, 33, 37, 38, 40, 41, 40.0 <0.001 
136, 167/, 173" 
DISCUSSION 
The predictability and relative ease with which permanent 
liver graft acceptance could be achieved made it possible to 
study a large group of animals the clinical-and presumably 
immunologic-status of which was stable after 100 or 300 days. 
These rats have been followed for as long as 1112 years. They 
were not immunologically depressed. They were healthy, vig-
orously rejected third-party or even donor-specific skin grafts, 
and possessed lymphocytes that were stimulated strongly in 
mixed lymphocytes culture of third-party alloantigens, and 
more weakly by donor-specific antigens. Not only could the 
recipient lymphoid tissue be shown to retain antidonor reactiv-
ity following allotransplantation, but weak graft-versus-host 
reactivity was identified in the recipient spleen. 
The conclusion was that long-term survival of the liver 
allografts was not due solely to classic tolerance. There was no 
evidence of a change in the lymphocyte population or lympho-
cyte subsets in the spleen or peripheral blood, and neither was 
there evidence of a crucial role of suppressor cells, either with 
in vitro or in vivo (MLR, splenectomy, and adoptive transfer) 
experiments. Nevertheless, it is intriguing that the frequency 
of heart graft prolongation was greater in the splenectomized 
animals, although not significantly so, and that there was a 
modest but significant prolongation of heart grafts after adop-
tive transfer. The experiments do not necessarily disprove 
accepted mechanisms of tolerance induction-but, taken to-
gether, they do not strongly support any of the monolithic 
theories of graft acceptance, including clonal deletion, active 
enhancement, suppressor cell activation, or antigen-antibody 
blockade of effector cells. The findings are not even fully 
compatible with a concatenation hypothesis (23) in which 
multiple immunologic changes could playa variable but rein-
forcing role. 
One possibility in a concatenation hypothesis that has not 
been ruled out is that the liver graft itself undergoes a change. 
The crucial experiment to determine this-namely, orthotopic 
retransplantation of a well tolerated ACI liver to a Lewis 
recipient-has not been done and may not be technically fea-
sible. However, it is known that the entire Kuppfer cell (mac-
rophage) system of the accepted liver changes rather quickly to 
that of the recipient in well-tolerated human grafts, while the 
hepatocytes, vascular endothelium, and carrier lymphoid tissue 
remain those of the donor (24). The switch to recipient status 
of the dendritic cell-rich macrophage system could be such a 
subtle event that its significance in liver graft acceptance has 
been overlooked. Other ways in which a graft could be modified 
may be suggested by the classic experime~ts on thyroid trans-
plantation by Woodruff and Woodruff (25). 
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TABLE 4. Effect of adoptive transfer of splenic lymphocytes from FKS06-treated LEW rats with ACI heart grafts on the acceptance of ACI 
hearts by naive LEW recipients 
Spleocyte Number Irradiation Survival MST Group ofCeU. ~ donor (250 rada) n (days) (daya) (X 10") 
II 7 6, 6, 6, 6, 6, 7, 7 6.0 
2 + 
" 
6,7,7,8 7.0 NS 
3 Normal LEW 200 + 
" 
6,6,7,10 6.S NS 
" 
FK-treated LEW with ACI heart 200 + 8 6,7,8,8, 10, 10, 10, 15 9.0 <0.01 (0.02) 
graft (28 days)' 
5 FK-treated LEW with ACI heart 200 + 6 7,7,7, 10, 10,20 8.5 0.01 (0.07) 
graft (70 dayal' 
• Wilcoxon ranlt sum test (Student's t test). 
• Control values from Table 1. 
• Spleen cells were pooled from 3 animals, each of which had functioning heart grafts for 28 days and more than 70 days. 
TABLE 5. Effect of adoptive transfer of splenic lymphocytes from FK506-treated LEW rats with ACI liver grafts on the acceptance of ACI 
livers by naive LEW recipienta 
Group 
1 
2 
3 
" 
Splenocyte 
donor 
Normal LEW 
FK-treated LEW with ACI liver 
gi-aft (100 daya)b 
FK-treated LEW with ACI liver 
graft (300 days)b 
• Wilcoxon rank sum teI!t. 
Num-
ber 
of cella 
(XIO") 
200 
200 
200 
Graft aurviYal 
n (days) 
10 9, 9, 9, 9, 10,10, 10, 
11,12, 13 
5 9, 9, 9, 10, 10 
7 8, 8, 10, 10, 11, 12, 12 
" 
9, 10,10,11 
MST 
(daya) 
10.0 
9.0 
10.0 
10.0 
NS 
NS 
NS 
b Splenocytes were pooled from " and 2 animals, each of which had functioning liver grafts for 100 and more than 300 days. 
It has been much harder to induce heart graft acceptance 
and the details of dose timing are more critical (1). The 
experiments showing limited privilege for a second heart from 
the same (but not a third-party) donor strain were carried out 
much earlier (14-28 clays) after the primary transplantation 
than in the liver experiments. In these experiments, the fate of 
the first and second hearts from the same donor strain was 
linked. When rejection occurred, it simultaneously effected 
both hearts as if the grafts were equal in the eyes of the immune 
system. It is possible that induction of heart graft acceptance 
is more difficult than that of liver because there is not a 
replacement of its dendritic cell-rich macrophage components. 
No studies of this important question are available to our 
knowledge. 
More work will be necessary before graft acceptance after 
short-term therapy, or failure to achieve this objective, can be 
understood. Then practical application could be close behind 
as increasingly powerful immunosuppressive agents become 
available for induction. Even in mongrel dogs, it has been 
possible using short courses of FK506 to have prolonged kidney 
and liver. graft survival (4, 26). In this species, as in the rat, 
the liver is "easier" than the kidney, but with both organs in 
outbred dogs an unqualified permanent success is the exception. 
However, what makes the exception could be the key to a new 
rule. 
Possible reasons for the easier acceptance of liver versus 
other organ grafts have been discussed elsewhere (27). It is 
possible that donor-specific HLA antigens that are produced 
by the new liver (28) could playa role. These HLA antigens 
u_"_,·u .. - I - t ;# 
appear very promptly after revascularization of human liver 
grmbE~FK . 
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